An integrated pan-cancer analysis of leucine-rich repeat containing protein 59: a potential biomarker for prognostic and immunotherapy

Abstract

Leucine-rich repeat containing protein 59 (LRRC59), a ribosome binding protein located on the endoplasmic reticulum and the nuclear envelope. Although it has been found in blood plasma and linked to the development of a few cancers, the function of LRRC59 is still largely unknown and there is no systematic investigation on its role in various human cancers. We performed a multi-omics data analysis to investigate the expression of LRRC59 in human tumors and its correlation with clinical prognosis, gene set enrichment, mutation status, and immune infiltration in cancers using the TCGA, GTEx, GEPIA2, HPA, UALCAN, Timer2, GTBAdb, cBioPortal database and R packages. In the majority of TCGA tumors, LRRC59 was expressed significantly differently (up-regulated in 25 and down-regulated in 4 cancer types). High LRRC59 expression has been linked to worse prognosis in several malignancies. In numerous carcinomas, the expression of LRRC59 was associated clinicopathological stages. The LRRC59 regulation network was mainly involved in the pathways related to endoplasmic reticulum homeostatic and cell proliferation. In addition, the expression of LRRC59 is also strongly associated with the immune cell infiltration. LRRC59 could also predicts the response to immunotherapy. LRRC59 is a potential valuable biomarker not only for diagnostic and prognostic, but also for immunotherapy in most cancers.

Keywords

LRRC59 / Pan-cancer / Prognosis / Biomarker / Immune infiltration

References

[1] Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho Y-J, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, et al. . The landscape of somatic copy-number alteration across human cancers. Nature. 2010, 463(7283): 899-905

[2] Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nature Communications. 2019, 10(1): 5679

[3] Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nature Reviews. Cancer. 2021, 21(2): 71-88

[4] Geng X, Zhang Y, Zeng Z, Zhu Z, Wang H, Yu W, Li Q. Molecular characteristics, prognostic value, and immune characteristics of m6A regulators identified in head and neck squamous cell carcinoma. Frontiers in Oncology. 2021, 11

[5] Hannigan MM, Hoffman AM, Thompson JW, Zheng T, Nicchitta CV. Quantitative proteomics links the LRRC59 interactome to mRNA translation on the ER membrane. Molecular & Cellular Proteomics: MCP. 2020, 19(11): 1826-1849

[6] Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nature Reviews. Molecular Cell Biology. 2020, 21(8): 421-438

[7] Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. Journal of Hematology & Oncology. 2019, 12(1): 71

[8] Li D, Xing Y, Tian T, Guo Y, Qian J. Overexpression of LRRC59 is associated with poor prognosis and promotes cell proliferation and invasion in lung adenocarcinoma. OncoTargets and Therapy. 2020, 13: 6453-6463

[9] Li S, Dong C, Chen J, Gao X, Xie X, Zhang X. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma. Aging. 2021, 13(12): 16696-16712

[10] Marciniak SJ, Chambers JE, Ron D. Pharmacological targeting of endoplasmic reticulum stress in disease. Nature Reviews. Drug Discovery. 2022, 21(2): 115-140

[11] Maurizio E, Wiśniewski JR, Ciani Y, Amato A, Arnoldo L, Penzo C, Pegoraro S, Giancotti V, Zambelli A, Piazza S, Manfioletti G, Sgarra R. Translating proteomic into functional data: An High Mobility Group A1 (HMGA1) proteomic signature has prognostic value in breast cancer. Molecular & Cellular Proteomics: MCP. 2016, 15(1): 109-123

[12] Ng ACY, Eisenberg JM, Heath RJW, Huett A, Robinson CM, Nau GJ, Xavier RJ. Human leucine-rich repeat proteins: A genome-wide bioinformatic categorization and functional analysis in innate immunity. Proceedings of the National Academy of Sciences of the United States of America. 2011, 108(Suppl 1): 4631-4638

[13] Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Pusey M, Nickels JT, Rice LM. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells. Tumour Biology: THe Journal of the International Society for Oncodevelopmental Biology and Medicine. 2015, 36(8): 6383-6390

[14] Pei L, Zhu Q, Zhuang X, Ruan H, Zhao Z, Qin H, Lin Q. Identification of leucine-rich repeat-containing protein 59 (LRRC59) located in the endoplasmic reticulum as a novel prognostic factor for urothelial carcinoma. Translational Oncology. 2022, 23

[15] Schulze A, Oshi M, Endo I, Takabe K. MYC targets scores are associated with cancer aggressiveness and poor survival in ER-positive primary and metastatic breast cancer. International Journal of Molecular Sciences. 2020, 21(21): 8127

[16] Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discovery. 2020, 10(12): 1808-1825

[17] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022, 72(1): 7-33

[18] Tatematsu M, Funami K, Ishii N, Seya T, Obuse C, Matsumoto M. LRRC59 regulates trafficking of nucleic acid-sensing TLRs from the endoplasmic reticulum via association with UNC93B1. Journal of Immunology (baltimore, Md.: 1950). 2015, 195(10): 4933-4942

[19] Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, Arai T, Maemura K, Fujii T, Horiguchi J, Natsugoe S, Seki N. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: Antitumor miR-204-5p targets AP1S3. Journal of Human Genetics. 2018, 63(12): 1197-1210

[20] van Schaijik B, Davis PF, Wickremesekera AC, Tan ST, Itinteang T. Subcellular localisation of the stem cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer: A review. Journal of Clinical Pathology. 2018, 71(1): 88-91

[21] Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD, Musselman-Brown A, Schmidt H, Amstutz P, Craft B, Goldman M, Rosenbloom K, Cline M, O’Connor B, Hanna M, Birger C, et al. . Toil enables reproducible, open source, big biomedical data analyses. Nature Biotechnology. 2017, 35(4): 314-316

[22] Xian H, Yang S, Jin S, Zhang Y, Cui J. LRRC59 modulates type I interferon signaling by restraining the SQSTM1/p62-mediated autophagic degradation of pattern recognition receptor DDX58/RIG-I. Autophagy. 2020, 16(3): 408-418

[23] Yu YP, Ding Y, Chen Z, Liu S, Michalopoulos A, Chen R, Gulzar ZG, Yang B, Cieply KM, Luvison A, Ren B-G, Brooks JD, Jarrard D, Nelson JB, Michalopoulos GK, Tseng GC, Luo J-H. Novel fusion transcripts associate with progressive prostate cancer. The American Journal of Pathology. 2014, 184(10): 2840-2849

[24] Zhen Y, Sørensen V, Skjerpen CS, Haugsten EM, Jin Y, Wälchli S, Olsnes S, Wiedlocha A. Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1. Traffic (copenhagen, Denmark). 2012, 13(5): 650-664